AR125450A1 - Anticuerpos anti-adgre2 y usos de los mismos - Google Patents

Anticuerpos anti-adgre2 y usos de los mismos

Info

Publication number
AR125450A1
AR125450A1 ARP220101068A ARP220101068A AR125450A1 AR 125450 A1 AR125450 A1 AR 125450A1 AR P220101068 A ARP220101068 A AR P220101068A AR P220101068 A ARP220101068 A AR P220101068A AR 125450 A1 AR125450 A1 AR 125450A1
Authority
AR
Argentina
Prior art keywords
antibodies
adgre2
fragments
fusion proteins
cancers
Prior art date
Application number
ARP220101068A
Other languages
English (en)
Inventor
Antara Banerjee
Xingyue He
Shawn Jennings
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of AR125450A1 publication Critical patent/AR125450A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen anticuerpos, fragmentos de los mismos y proteínas de fusión que se unen específicamente a ADGRE2, así como métodos preparación y uso de tales anticuerpos. Estos anticuerpos, proteínas de fusión y fragmentos de los mismos son de utilidad para el tratamiento y el diagnóstico de diversas enfermedades autoinmunes y cánceres, incluyendo, por ejemplo, leucemia mieloide aguda.
ARP220101068A 2021-04-26 2022-04-25 Anticuerpos anti-adgre2 y usos de los mismos AR125450A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163179756P 2021-04-26 2021-04-26

Publications (1)

Publication Number Publication Date
AR125450A1 true AR125450A1 (es) 2023-07-19

Family

ID=81648880

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101068A AR125450A1 (es) 2021-04-26 2022-04-25 Anticuerpos anti-adgre2 y usos de los mismos

Country Status (16)

Country Link
US (1) US20230018888A1 (es)
EP (1) EP4330283A1 (es)
JP (1) JP2024518776A (es)
KR (1) KR20240004287A (es)
CN (1) CN117580860A (es)
AR (1) AR125450A1 (es)
AU (1) AU2022266583A1 (es)
BR (1) BR112023020371A2 (es)
CA (1) CA3214355A1 (es)
CL (1) CL2023003174A1 (es)
CO (1) CO2023013195A2 (es)
EC (1) ECSP23088752A (es)
IL (1) IL307940A (es)
MX (1) MX2023011712A (es)
TW (1) TW202305003A (es)
WO (1) WO2022232035A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024089622A1 (en) * 2022-10-25 2024-05-02 Takeda Pharmaceutical Company Limited Adgre2 chimeric receptor nk cell compositions and methods of use

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
EP0228458B2 (en) 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
DE3852823T2 (de) 1987-09-11 1995-05-24 Hughes Howard Med Inst Transduktionsveränderte fibroblasten und ihre anwendung.
EP0391960B1 (en) 1987-12-11 1994-08-17 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
EP0400047B1 (en) 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU656544B2 (en) 1990-10-31 1995-02-09 Brigham And Women's Hospital Genetic modification of endothelial cells
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
ATE547080T1 (de) 2000-08-30 2012-03-15 Univ Johns Hopkins Vorrichtungen zur intraokularen arzneimittelabgabe
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
DK1432466T3 (da) 2001-09-12 2012-12-03 Becton Dickinson Co Mikronål-baseret penapparat til lægemiddeludlevering og fremgangsmåde til anvendelse heraf
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
WO2004073551A2 (en) 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
WO2009011782A2 (en) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR
KR20120138241A (ko) 2010-03-11 2012-12-24 화이자 인코포레이티드 ｐＨ 의존성 항원 결합을 갖는 항체
EP2622074B1 (en) 2010-09-30 2014-11-12 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
SG189475A1 (en) * 2010-11-05 2013-05-31 Transbio Ltd Markers of endothelial progenitor cells and uses thereof
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CN108430516A (zh) * 2015-11-19 2018-08-21 艾伯维施特姆森特克斯有限责任公司 新颖抗emr2抗体和使用方法
EP3344263A4 (en) * 2016-08-04 2020-07-01 Memorial Sloan-Kettering Cancer Center CANCER ANTIQUES AND USES THEREOF

Also Published As

Publication number Publication date
AU2022266583A1 (en) 2023-10-19
CA3214355A1 (en) 2022-11-03
ECSP23088752A (es) 2024-01-31
WO2022232035A1 (en) 2022-11-03
BR112023020371A2 (pt) 2024-02-06
EP4330283A1 (en) 2024-03-06
CL2023003174A1 (es) 2024-05-24
CO2023013195A2 (es) 2023-10-19
AU2022266583A9 (en) 2023-10-26
US20230018888A1 (en) 2023-01-19
TW202305003A (zh) 2023-02-01
JP2024518776A (ja) 2024-05-02
IL307940A (en) 2023-12-01
KR20240004287A (ko) 2024-01-11
CN117580860A (zh) 2024-02-20
MX2023011712A (es) 2023-10-12

Similar Documents

Publication Publication Date Title
CO2019013611A2 (es) Anticuerpos específicos para flt3 y sus usos
ECSP20082991A (es) Agentes aglutinantes del psma y usos de estos
CO2020014575A2 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
CO2019003923A2 (es) Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CO2017005240A2 (es) Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción
CL2019003520A1 (es) Anticuerpos que se unen específicamente a pd-1 y procedimientos de uso.
ECSP23088752A (es) Anticuerpos anti-adgre2 y usos de los mismos
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
PE20220142A1 (es) Anticuerpos de cadena pesada que se unen al psma
UY37591A (es) Conjugados de fármaco anticuerpo
CR20120086A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
CL2020002144A1 (es) Proteínas de unión multiespecíficas que se unen a cd33, nkg2d y cd16 y métodos de uso, (solic. hna 2143)
CL2020000576A1 (es) Anticuerpos de la proteína de muerte celular programada 1
CO2020005347A2 (es) Anticuerpos y conjugados de anticuerpo-fármaco específicos para cd123 y usos de los mismos
AR113223A1 (es) Anticuerpo monoclonal para pd-l1
ECSP17080733A (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
ECSP20039728A (es) Anticuerpos monoclonales y métodos para utilizar los mismos
EA202092302A1 (ru) Антитела к trem-1 и их применения
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
CO2024004055A2 (es) Polipéptidos
CO2023014316A2 (es) Anticuerpos anti-clec12a y usos de los mismos
CO2022015030A2 (es) Anticuerpos anti-cd19 y sus usos